566949-37-9

Upstream product

• 22666-84-8 4-hydroxybenzaldehyde sodium salt 
• 86864-60-0 2-(tert-butyldimethylsilyloxy)ethyl bromide 
• 68-12-2 N,N-dimethyl-formamide 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 22042-73-5 4-(2-hydroxy-ethoxy)-benzaldehyde 

Downstream Products

• 1434515-69-1 (E)-1-(4-(2-((tert-butyldimethylsilyl)oxy)ethoxy)phenyl)-7-(4-chlorophenyl)hept-6-en-1-yn-3-one 
• 1434515-73-7 C₂₇H₃₁ClO₃Si 
• 1434515-78-2 9-(4-(2-((tert-butyldimethylsilyl)oxy)ethoxy)phenyl)-7-(dimethylamino)-2,3-dihydro-1H-cyclopenta[b]naphthalen-1-one 
• 1434515-82-8 7-(dimethylamino)-9-(4-(2-hydroxyethoxy)phenyl)-2,3-dihydro-1H-cyclopenta[b] naphthalen-1-one 
• 1434515-59-9 tert-butyl(2-(4-ethynylphenoxy)ethoxy)dimethylsilane 
• 1434515-57-7 tert-butyl(2-(4-(2,2-dibromovinyl)phenoxy)ethoxy)dimethylsilane 
• 1056555-18-0 4-azido-N-cyclopropyl-N-(2,3-dichlorobenzyl)-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}butanamide 
• 921629-11-0 4-amino-N-cyclopropyl-N-(2,3-dichlorobenzyl)-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}butanamide 
• 1056554-97-2 N-cyclopropyl-N-(2,3-dichlorobenzyl)-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-4-hydroxybutanamide 
• 1056554-96-1 N-cyclopropyl-N-(2,3-dichlorobenzyl)-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}pent-4-enamide 
• 1056554-99-4 ethyl 2-{4-[(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}pent-4-enoate 
• 1056554-95-0 2-{4-[(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}pent-4-enoic acid 
• 1056555-57-7 ethyl 2-[4-(2-{[tert-butyl(dimethyl)silyl]oxy}ethoxy)benzyl]pent-4-enoate 
• 1056555-58-8 ethyl 2-[4-(2-hydroxyethoxy)benzyl]pent-4-enoate 

Relevant academic research and scientific papers

Compounds and Their Use in Treating Cancer

The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts and prodrugs thereof, where R1, R4, R5, R6, R7, Linker, X, Y, A, G, D and E have any of the meanings defined herein. This specification also relates to the use of such compounds and pharmaceutically acceptable salts and prodrugs thereof in methods of treatment of the human or animal body, for example in prevention or treatment of cancer. This specification also relates to processes and intermediate compounds involved in the preparation of such compounds and to pharmaceutical compositions containing them.

The flocculated acryloyldimethyltauric molecule ligand

Provided are certain benzothiazole, imidazothiazole, imidazopyrimidine and imidazopyridine compounds, including, for example: formula (I) and pharmaceutically and physiologically acceptable salts, hydrates, and solvates thereof. Such compounds can be used as diagnostic ligands or labels of tau protein and PHF.

PIPERIDINE-DIONE DERIVATIVES

The invention provides novel compounds having the general formula (I) and tautomers and pharmaceutically acceptable salts thereof, wherein A1, A2, A3, A4, R1, R4, R5, R6, R7 and R8 are as defined herein, compositions including the compounds and methods of using the compounds.

RENIN INHIBITORS

The present invention relates to novel renin inhibitors of the general Formula (I), and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds. These novel renin inhibitors are used in treating cardiovascular events and renal insufficiency.

Fused pyridine derivatives

The present provides a condensed pyridine compound (I) represented by the following formula: (wherein, R2represents ring A represents benzene ring, pyridine ring, thiophene ring or furan ring; and B represents its pharmaceutically acceptable salt or hydrates thereof, which is a clinically useful medicament having a serotonin antagonism, in particular, that for treating, ameliorating or preventing spastic paralysis or central muscle relaxants for ameliorating myotonia.